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Abstract
Background: The leading cause of death in end stage renal disease is cardiovascular disease (CVD). Kidney
transplantation is associated with improved survival over dialysis. We hypothesized that arterial stiffness, a marker
of CVD, would improve in patients post kidney transplant, potentially explaining one mechanism of survival benefit
from transplant.
Methods: After obtaining Institutional Review Board approval and informed consent, we performed a longitudinal
prospective cohort study of 66 newly transplanted adult kidney transplant recipients, using aortic pulse wave velocity
(PWV) to assess arterial stiffness over a 12 month period. All patients were assessed within one month of transplant
(baseline) and 12 months post transplant. The primary outcome was change in PWV score at 12 months which we
assessed using Wilcoxon Signed Rank test. Secondary analyses included correlation of predictors with PWV score at
both time points.
Results: The median age of the cohort was 49.7 years at transplant, with 27 % Black and 27 % female. At baseline,
43 % had tobacco use, 30 % had a history of CVD, and 42 % had diabetes. Median baseline calcium was 9.1 mg/dL
and median phosphorus was 5.1 mg/dL. Median PWV score was 9.25 and 8.97 m/s at baseline versus month 12,
respectively, showing no significant change (median change of −0.07, p = 0.7). In multivariable regression, subjects
with increased age at transplant (p = 0.008), diabetes (p = 0.002), and a higher baseline PWV score (p < 0.001) were at
increased risk of having a high PWV score 12 months post transplant.
Conclusion: Aortic arterial stiffness does not progress in the first year post kidney transplant. Increasing age, diabetes,
and higher baseline PWV score identify patients at risk for increased arterial stiffness. Further research that assesses
patients for greater than one year and includes a control dialysis group would be helpful in further understanding the
change in arterial stiffness post transplantation.
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Background
Cardiovascular disease (CVD) exerts a heavy burden in
patients with chronic kidney disease (CKD), and it is the
leading cause of death in the end stage renal disease
(ESRD) population [1–3]. Contributors to CVD in ESRD
include vascular arterial calcifications from abnormal
mineral metabolism and inflammation related to poor
kidney function. Kidney transplantation leads to im-
proved survival compared to wait-listed dialysis patients,
making it the renal replacement therapy of choice in eli-
gible patients [4]. The reasons for this survival advantage
are likely multifactorial, but include improved cardiovas-
cular risk as a result of return of kidney function [5–7].
Even so, kidney transplant recipients continue to have a
high burden of CVD, with CVD being the number one
cause of death with a functioning transplant [1].
Increased aortic arterial stiffness is strongly associated
with the development of CVD and is an independent
predictor of cardiac and all-cause mortality [8]. Aortic
pulse wave velocity (PWV) provides a non-invasive me-
thod to assess aortic arterial stiffness [8, 9]. Though
often used in the research setting, several studies sup-
port using PWV in the clinic based on its reported asso-
ciations with cardiovascular risk and all-cause mortality
in a variety of patient populations, with one meta-
analysis showing each increase of 1 m/s in aortic PWV
being associated with a 15 % risk-adjusted increase in
both cardiovascular and all-cause mortality [10]. Similar
findings have been demonstrated specifically in patients
with CKD and on maintenance dialysis, with PWV
increasing over time in maintenance dialysis patients
[11–14]. Higher aortic PWV has also been associated
with all-cause mortality and cardiovascular events in few
studies of prevalent kidney transplant recipients, but less
is known about changes that may occur in arterial stiffness
over time after successful kidney transplantation [15, 16].
We hypothesized that aortic arterial stiffness would be
improved in patients receiving a kidney transplant, po-
tentially explaining one mechanism of survival benefit
from transplant. In this study we examined a prospective
cohort of 66 kidney transplant recipients with aortic PWV
measurements and assessed the changes in aortic arterial
stiffness over the first year post kidney transplant.
Methods
Study design
All study procedures were approved by the Institutional
Review Board (IRB) of Vanderbilt University Medical
Center (VUMC). Informed consent was obtained from
all study participants. We conducted a single-center,
prospective cohort study of 66 newly transplanted adult
kidney transplant recipients, using pulse wave velocity
(PWV) to assess arterial stiffness over a 12 month
period. Kidney transplant recipients were consecutively
recruited from the VUMC Renal Transplant Clinic from
August 2009 through September 2012. Inclusion criteria
included patients aged ≥ 18 who were undergoing or had
recently undergone kidney transplantation. Participants
were excluded if they were unwilling to participate or
had atrial fibrillation, since this condition makes pulse
wave velocity testing uninterpretable. Induction therapy
was alemtuzumab with methylprednisolone in 85 % of
patients. All patients were maintained on tacrolimus and
mycophenolate. Maintenance steroids were used in 9 %.
Tacrolimus was dosed to a 12 h trough blood concentra-
tion of 8–10 ng/ml the first 6 months, then of 6–8 mg/ml
for months 6 through 12.
The study was composed of two visits, with patients
assessed within 1 month of transplant (baseline) and
12 months post transplant. Demographic, medical, and
social data was collected from each participant and
confirmed in the electronic medical record. Participants
underwent pulse wave velocity testing by a trained pro-
fessional at the Vanderbilt Clinical Research Center using
the SphygmoCor CPV Pulse Wave Velocity system (AtCor
Medical, Sydney, Australia). Briefly stated, pulse wave
velocity is the time it takes the arterial pressure wave to
travel between two arterial sites, where PWV= distance
(meters)/transit time (seconds). A higher PWV positively
correlates with increased arterial stiffness. A more detailed
description of pulse wave velocity procedure has been pre-
viously published [8]. In this study the carotid to femoral
distance was selected, representing aortic arterial stiffness.
The distance was measured by subtracting the distance
between the carotid site and sternal notch from the dis-
tance between the sternal notch and the femoral site. For
participants who were hemodialysis patients with vascular
accesses, measures were taken on the non-access side.
After resting 10 min in a supine position, hemodynamic
measurements were obtained for each participant. All
measurements were performed twice with the average of
the two values used for analysis.
Statistical analysis
We expressed descriptive statistics as proportions for
categorical variables and as means and standard devia-
tions, or medians and interquartile ranges for conti-
nuous variables, depending on the distribution of the
variables. The primary outcome was change in PWV
score at 12 months from baseline, which we assessed
using Wilcoxon Signed Rank test. We further assessed
the change in PWV score stratified by subjects’ diabetes
status at baseline. Secondary analyses included predic-
tors of PWV score at baseline and at 12 months post
transplant. Spearman’s rank correlation was used to test
the association of age at baseline with PWV score at
baseline and 12 months as well as the association of
PWV score at baseline and at 12 months. We further
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conducted multivariable regression to determine pre-
dictors for both baseline and 12 month PWV mea-
sures. Age at transplantation, race, gender, diabetes
status, and time in months on dialysis at baseline
were included as potential predictors. Baseline PWV
score was also included in the multivariable model to
predict PWV score at 12 month post transplant. Nor-
mality of residuals of all linear models was diagnosed
figuratively. We conducted all analyses using R-
software version 2 · 11 · 1 (www.r-project.org) and used
a two-sided 5 % significance level for all statistical
analyses.
Results
Seventy-eight kidney transplant recipients were enrolled
into the study. Sixty-six of these had pulse wave velocity
measures available at baseline and at 12 months post
transplant. Characteristics of the study cohort are pre-
sented in Table 1. The median age of the cohort was
49.7 years at transplant, with 27 % black and 27 % female.
At baseline, 43 % had tobacco use, 27 % had a history of
CVD, and 42 % had diabetes. Mean blood pressure was
136/79 mmHg at baseline and 131/77 mmHg at month
12, with 94 % of the cohort with pre-existing diagnosis of
hypertension. Baseline calcium was 9.1 mg/dL and phos-
phorus was 5.1 mg/dL. The median duration of dialysis
prior to transplant was 1.74 years, though 18 % of recipi-
ents had no dialysis time (pre-emptive transplant). At
baseline, median serum creatinine was 8.4 mg/dL and esti-
mated glomerular filtration rate (eGFR) was 10 mL/min/
1.73 m2. Median serum creatinine 12 months post kidney
transplant was 1.4 mg/dL, corresponding to an eGFR
61 mL/min/1.73 m2.
The median PWV was 9.25 m/s at baseline. At month
12 it was 8.97 m/s, showing no significant change in
PWV over the study period (median change of −0.07,
p = 0.7; Fig. 1a). Twenty-five (37.9 %) of the participants
had a PWV at baseline greater than or equal to 10 m/s,
indicating severe arterial stiffness at the time of trans-
plant. Overall, about half the kidney transplant recipients
showed an increase in PWV over 12 months, while the
other half decreased, with no relation to PWV at base-
line (Fig. 1b). Prior to analysis, we hypothesized diabetes
would have an effect on PWV. Therefore we assessed
the change in PWV in kidney transplant recipients with
and without diabetes. As seen in Fig. 2, though patients
without diabetes trended to a decrease in PWV and pa-
tients with diabetes an increase in PWV, these changes
were not significant within or between the groups. Over-
all 8 new cardiovascular events were observed during
the 12 month follow up period.
Our secondary analyses centered on predictors of
PWV at baseline and at 12 months. Using Spearman cor-
relation, age strongly correlated with pulse wave velocity
at baseline, showing increasing age with increasing baseline
value (rho = 0.59, P < .001). Neither time on dialysis nor
the calcium-phosphorus product prior to transplant corre-
lated with PWV at baseline. For PWV at 12 months, both
PWV at baseline (rho = 0.87, p < .001) and age (rho = 0.61,
P < .001) were significantly correlated. No significant
Table 1 Characteristics of the 66 kidney transplant recipients
Characteristic
Age at transplant (years) 49.7 (41, 61)
Race
White 46 (70 %)
Black 18 (27 %)
Other 2 (3 %)
Sex (female) 18 (27 %)
Tobacco use
Never 37 (57 %)
Current 5 (8 %)
Former 23 (35 %)
Cardiovascular disease pre transplanta 18 (27 %)
Diabetes pre transplant 28 (42 %)
Primary cause end stage renal disease
Diabetes 21 (32 %)
Hypertension 13 (20 %)
Glomerulonephritis 11 (17 %)
Cystic 10 (15 %)
Other 11 (17 %)
Serum creatinine (mg/dL)
Pre transplant 8.4 (6.2, 9.7)
1 month post transplant 1.5 (1.2, 1.7)
12 months post transplant 1.4 (1.2, 1.6)
Estimated glomerular filtration rate
(mL/min/1.73 m2)
Pre transplant 8.3 (6, 10.5)
1 month post transplant 53.7 (45.5, 69.9)
2 months post transplant 61 (47.8, 70.4)
Calcium pre transplant (mg/dL) 9.1 (8.5,9.5)
Phosphorus pre transplant (mg/dL) 5.1 (4.2, 6.5)
Systolic blood pressure (mm Hg)
Baseline 136.2 (123, 149)
Month 12 131.3 (120.5, 143)
Diastolic blood pressure (mm Hg)
Baseline 79 (72, 84)
Month 12 77.1 (42, 83)
Time on dialysis prior to transplant (days) 636 (362, 1254)
Values expressed as median (25th, 75th percentiles) or number (percent)
aCardiovascular disease includes coronary artery disease, stroke, and peripheral
vascular disease
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correlation was seen between serum creatinine at
12 months and PWV at 12 months. Results for multivari-
able regression are shown in Table 2. Increased age at
transplant and presence of diabetes were significant pre-
dictors of higher PWV at baseline. Similarly, significant
predictors of higher PWV at 12 months were increased
age and diabetes at time of transplant, as well as higher
PWV at baseline.
Discussion
Patients who undergo kidney transplantation have im-
proved survival and lower cardiovascular risk relative to
wait-listed dialysis patients. This suggests that transplant
may positively impact cardiovascular risk. Though this
effect likely occurs through several processes, here we
examined the effect of kidney transplantation on arterial
stiffness by assessing PWV. In this prospective study of
66 new kidney transplant recipients, we showed that
there was no change in aortic PWV over the first year
post kidney transplant, suggesting arterial stiffness does
not progress during this time period. Increasing age,
having diabetes and higher baseline PWV score were
associated with increased PWV score at 12 months
and may help identify patients with increased arterial
stiffness.
Previous studies have suggested that PWV progresses
with time on dialysis. For example, Utescu and col-
leagues showed an annual increase of 0.84 m/s per year
(95 % CI 0.50−1.12 m/s per year) in a cohort of 109
hemodialysis patients [12]. In another study of 88 wait-
listed patients in which 39 were transplanted and 49
were not, during one year follow up no difference was
Fig. 1 a Box plot of change in PWV from baseline to month 12 in 66 kidney transplant recipients. b Individual line plots of PWV change from
baseline to month 12 in each kidney transplant recipient, stratified by positive or negative change
Fig. 2 Box plot of change in PWV from baseline to month 12 in kidney
transplant recipients with and without diabetes prior to transplant
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seen in PWV between the 2 groups, though follow up
time for those transplanted was short (median 6.3
months) [17]. In our study, in contrast to dialysis pa-
tients, we did not see PWV progression over the first
year post transplant. One interpretation could be that
restoration of kidney function with transplant has a posi-
tive impact on slowing the process of arterial stiffness.
However, further study is needed to see if this trend con-
tinues over longer time periods, and more importantly if
this is associated with decreased CVD events. Given the
adverse metabolic effects of routinely used immunosup-
pression drugs, it is possible that with more time the
balance shifts the opposite direction.
For kidney transplant recipients, prior cross-sectional
studies have shown that transplant recipients have
higher aortic PWV measurements than historical healthy
controls. The reported median normal values for a large
European population of individuals aged 40–49 was
6.9 m/s and aged 50–59 was 8.1 m/s compared to
9.25 m/s in our patient cohort with a median age of
49.7 years [9]. In a retrospective study, 106 patients in
Lebanon at a mean 54.1 months post transplant had mean
aortic PWV of 11.1 ± 2.8 m/s compared to 8.7 ± 1.6 m/s in
a previously studied healthy male cohort. The mean PWV
value in that study was much higher than what we ob-
served in our cohort. In addition, the transplant recipients
who had experienced more cardiovascular events at time
of PWV assessment had a significantly higher aortic PWV
than those who did not (12.8 ± 4.3 vs 10.9 ± 2.5 m/s, re-
spectively, p < 0.05) [18]. Similarly a study from Belgium
of primarily white patients showed a higher baseline
measure of PWV was associated with more cardiovascular
events after a mean follow up of 5 years (11.2 vs 9.2 m/s,
p < 0.001) [19].
These prior studies had single time points of PWV as-
sessments of prevalent transplant recipients, with pa-
tients enrolled at varying times post transplantation. Our
study was different in that it followed incident patients
from time of transplant, with measurements at baseline
and one year, adding further information about what
happens to PWV over time. Our results indicate that
changes in aortic stiffness may be slowed with successful
transplantation, consistent with two previous smaller
studies over a shorter time period of 3 months [20, 21].
In the study by Ignace, et al. aortic stiffness changes
post transplantation were dependent on age, with im-
provement seen only in transplant recipients older than
50 years [21]. A previous study by Zoungas, et al. ob-
served aortic PWV in patients over 1 year showing a
slight improvement, but the majority of these patients
were on cyclosporine [15]. Our study has similar find-
ings but in tacrolimus treated patients, which is import-
ant since tacrolimus is the most commonly prescribed
calcineurin inhibitor, used as the initial choice in 91 % of
patients in the United States [1]. To our knowledge this
is the first study to report carotid PWV in a cohort
entirely maintained on tacrolimus of this duration. A
Japanese study of 58 patients on tacrolimus followed
only up to 6 months post transplantation showed a de-
crease in brachial-ankle PWV in a low risk population of
younger (mean age 40.5 years) kidney transplant recipi-
ents [22].
In contrast to our study, a study in Poland found that
carotid PWV increased with time post transplantation,
but these patients were already a median time of
36 months post transplantation at time of enrollment, dif-
fering from our population of newly transplanted patients.
Similar PWV values to those in our study were observed
in the 61 kidney transplant recipients with an eGFR of 55
mL/min/1.73 m2, where the initial measured carotid PWV
was 9.1 m/s. In this group, however, PWV increased to
9.8 m/s when measured 24 months later [23]. One pos-
sible explanation for this finding was the prolonged expos-
ure to transplant immunosuppression. Indeed, some
studies have examined the effects of different classes of
immunosuppression on aortic stiffness. In a randomized
study in France, low cardiovascular risk groups of newly
transplanted kidney patients were maintained on cy-
closporine or randomized to sirolimus at week 12 and
followed for a variety of cardiovascular related outcomes,
including carotid PWV, for 1 year. Those in the sirolimus
group had significantly lower PWV at follow up [24]. Simi-
larly, another study compared carotid PWV in kidney
transplant recipients on belatacept versus calcineurin in-
hibitors, and found after 5 years post transplantation,
Table 2 Multivariable linear regression model of PWV in kidney
transplant recipients
Covariate Effect S.E. 95 % CI P
Predictors of PWV at baseline
Age at transplant 2.8 0.5 1.8–3.8 <0.0001
Non-white race 0.4 0.6 −0.8–1.6 0.5
Female sex 0.5 0.6 −0.7–1.7 0.4
Diabetes pre transplant 2.5 0.6 1.4–3.6 <0.0001
CVD pre transplanta 0.9 0.6 −0.4–2.1 0.2
Time on dialysis 0.2 0.3 −0.3–0.7 0.5
Predictors of PWV at 12 months
PWV at baseline 2 0.3 1.5–2.6 <0.0001
Age at transplant 1.1 0.4 0.3–1.9 0.01
Non-white race 0.4 0.4 −0.4–1.2 0.4
Female sex 0.5 0.4 −0.3–1.3 0.2
Diabetes pre transplant 1.5 0.4 0.6–2.3 0.001
CVD pre transplanta 0.04 0.4 −0.8–0.9 0.9
Time on dialysis 0.2 0.2 −0.2–0.5 0.4
aCardiovascular disease (CVD) includes coronary artery disease, stroke, and
peripheral vascular disease
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more patients in the calcineurin inhibitor group had a
PWV greater than 8.1 m/s than in the belatacept group
[25]. These studies support that calcineurin inhibitors may
have more detrimental cardiovascular effects long term.
Strengths of our study included the prospective longi-
tudinal design and duration of follow up, including the
fact that all patients started follow up at time of their
transplant, so they all had been exposed to transplant
immunosuppression the same length of time. In ad-
dition, a large percent of the cohort was black, allowing
study of a population not frequently available in other
cohorts of kidney transplant recipients. A weakness was
our inability to adjust for multiple covariates without
overfitting the model due to our relatively small sample
size, though we were able to adjust for all demographics
and important cardiovascular risk factors like diabetes
and pre-existing cardiovascular disease. Also due to the
small number of cardiovascular events in this study
current cohort, we were not able to test associations of
PWV with these. In addition, overall our population was
a low risk population for acute rejection and low risk for
immediate cardiovascular events due to our selection
process pre transplant.
Conclusions
In a prospective study of new kidney transplant recipi-
ents treated with tacrolimus, we showed that there was
no change in aortic PWV over the first year post kidney
transplantation, suggesting arterial stiffness does not
progress during this time period in a cohort of low risk
individuals for cardio-renal outcomes. Further prospec-
tive research regarding arterial stiffness after transplant
would be helpful to better understand the impact of
transplant on cardiovascular risk. Specifically studies
with longer follow-up time and with adequate number
of cardiovascular events are necessary. Ultimately this
may help identify kidney transplant patients at higher
risk for CVD events and to target for intervention.
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